AI-generated · cited to primary sources · not investment advice
Anthem Bioscienc (544449) Aug 2025 Filing Analysis
Does management do what it says?
The fermentation block at Unit III (NeoAnthem) is still expected to be commissioned by the end of the year. (1 in progress, 2 met across 3 tracked commitments)
“Fermentation 142 kiloliters, we are adding 40 kiloliters more in NeoAnthem, which should also get done in this calendar year.”
See the full cited Management analysis of Anthem Bioscienc
How durable is the business?
The CRDMO segment showed significant expansion, delivering INR 452.7 crores in revenue for Q1 FY26, driven by increased demand for commercialized products from 5-6 key clients. (5 expanding)
“The CRDM business delivered INR452.7 crores revenues out of that... The strong year-on-year growth in this quarter FY26 reflects our CRDM or revenue stream that started ramping up in Q2 of FY25.”
The company is expanding its technological moat by commissioning commercial-scale facilities for new modalities like ADCs (Antibody-Drug Conjugates) and Peptides. (2 expanding)
“With respect to the modalities... we have upgraded ourselves from being a lab-scale facility in some of these modalities to commercial-scale facilities. So ADCs... we have now commissioned the new Anthem commercial-scale facility. Peptides also, we have commissioned the commercial-scale facility.”
See the full cited Business Model analysis of Anthem Bioscienc
Where does growth come from?
Margins remain healthy but have stabilized at a lower level (38%) compared to previous full-year peaks, though management expects them to remain steady in this 'zip code'. (1 steady across 1 signal)
“The EBITDA was INR214.3 crores with the margins, EBITDA margins at 38%.”
See the full cited Future Growth analysis of Anthem Bioscienc
What could break the thesis?
Concentration risk is slightly intensifying as CRDMO revenue grew 70.5% YoY, now accounting for 83.8% of total revenue compared to 83.9% in the previous quarter, maintaining a heavy reliance on this single segment. (2 intensifying, 3 easing)
“Q1FY26 Revenue Split: CRDMO 83.8%, Specialty Ingredients 16.2%”
See the full cited Risk analysis of Anthem Bioscienc
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.